Candidiasis Clinical Trial Pipeline Analysis: 15+ Key Companies Shaping the Future of Candidiasis Therapeutics | DelveInsight

DelveInsight's Candidiasis Pipeline Insight 2026 report provides comprehensive global coverage of available and pipeline Candidiasis therapies across various stages of clinical and nonclinical development. More than 15 companies are working to advance 15+ pipeline drugs, with pharmaceutical and biotechnology companies developing novel antifungal approaches to address the treatment challenges and unmet needs associated with Candidiasis.

Key takeaways from the Candidiasis Clinical Trial Landscape Report

• DelveInsight's Candidiasis pipeline report depicts a developing space with 15+ active players working to develop 15+ pipeline therapies for Candidiasis treatment.
• Key Candidiasis companies such as Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, and others are involved in developing therapies for the indication.
• Promising Candidiasis pipeline therapies in various stages of development include HRS9432, MAT2203, Prof-001, CelAgace, SCY-078, NDV-3, NP339, and others.
• The Candidiasis pipeline includes Phase III, Phase II, Phase I, preclinical, discovery, discontinued, and inactive candidates, reflecting a diverse therapeutic development landscape.
• Jiangsu Hengrui Medicine has HRS9432 in the most advanced active development stage highlighted on the report page, Phase II.

Request a sample and discover the recent advances in Candidiasis treatment drugs:
https://www.delveinsight.com/sample-request/candidiasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Candidiasis?

Candidiasis is an infection caused by a fungus of the Candida genus, most commonly Candida albicans. The infection generally affects the skin and/or mucous membranes of areas such as the mouth, intestines, and vagina. In otherwise healthy individuals, candidiasis is rarely serious; however, in people with impaired immune function, the infection can spread to other parts of the body.
In severe cases, candidiasis may affect the bloodstream, the membrane lining the heart muscle (endocardium), or the membranes surrounding the brain (meninges). Candida is normally present in healthy individuals, but its growth can become excessive when factors such as chemotherapy or broad-spectrum antibiotics suppress normal bacterial flora. Conditions including pregnancy and diabetes mellitus may also increase susceptibility to Candida infection.
The clinical presentation varies widely, ranging from relatively mild and common oral or vaginal infections to rare and severe systemic infections involving major organs. The disease management landscape includes antifungal therapies and emerging approaches designed to address fungal infections, particularly in immunocompromised populations.

Emerging Candidiasis Drug Profiles

HRS9432: Jiangsu Hengrui Medicine
HRS9432 is a long-acting echinocandin antifungal medication primarily designed to treat invasive fungal infections, particularly invasive candidiasis. Clinical trials have assessed the safety and tolerability of HRS9432 in healthy subjects through randomized, double-blind, dose-escalation study designs. The available clinical data indicate that HRS9432 was generally well tolerated, with manageable side effects in the studied populations. HRS9432 is currently in Phase II development for Candidiasis.

MAT2203: MATINAS BIOPHARMA HOLDINGS
MAT2203 is an oral and non-toxic enco¬chleated formulation of amphotericin B (CAmB) developed using the company's LNC technology. Amphotericin B is a broad-spectrum antifungal treatment used particularly in immunocompromised patients. MAT2203 is designed to deliver the antifungal agent directly to infected tissues while reducing unnecessary systemic exposure and associated toxicity. MAT2203 is currently in Phase II development for Candidiasis.

Prof-001: ProFem GmbH
Prof-001 is among the emerging pipeline products being evaluated in the Candidiasis therapeutic landscape. The candidate is being developed by ProFem GmbH as part of the company's efforts to address Candida infections through novel therapeutic approaches.

Learn more about the novel and emerging Candidiasis pipeline therapies:
https://www.delveinsight.com/sample-request/candidiasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Candidiasis Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Late Stage Products (Phase III), Mid-stage Products (Phase II), Early-stage Products (Phase I), Preclinical and Discovery Stage Candidates, Discontinued & Inactive Candidates
• Therapeutics Assessment By Route of Administration: Inhalation, Inhalation/Intravenous/Oral, Intranasal, Intravenous, Intravenous/Subcutaneous, NA, Oral, Oral/intranasal/subcutaneous, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
• Key Candidiasis Companies: Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, and others
• Key Candidiasis Pipeline Therapies: Rezafungin, MAT2203, Prof-001, CelAgace, SCY-078, NDV-3, NP339, MSC Candida, VT-1598, BCM-0882, BCM-0915, MCZ-DB, HRS9432, and others.

Dive deep into rich insights for new drugs for Candidiasis treatment, visit:
https://www.delveinsight.com/sample-request/candidiasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Candidiasis Pipeline Report Introduction
2. Candidiasis Pipeline Report Executive Summary
3. Candidiasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Candidiasis Pipeline Therapeutics
6. Candidiasis Pipeline: Late Stage Products (Phase III)
7. Candidiasis Pipeline: Mid Stage Products (Phase II)
8. Candidiasis Pipeline: Early Stage Products (Phase I)
9. Candidiasis Pipeline: Preclinical and Discovery Stage Products
10. Candidiasis Pipeline Therapeutics Assessment
11. Inactive Products in the Candidiasis Pipeline
12. Candidiasis Key Companies
13. Candidiasis Key Products in the Pipeline
14. Candidiasis - Unmet Needs
15. Candidiasis - Market Drivers and Barriers
16. Candidiasis - Future Perspectives and Conclusion
17. Candidiasis Analyst Views
18. Appendix

For further information on the Candidiasis pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/candidiasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: ksharma@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.